

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GLORY 国瑞

Glory Health Industry Limited

國瑞健康產業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2329)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director**”) of Glory Health Industry Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. Liu Chengjiang (“**Mr. Liu**”) has been appointed as an independent non-executive director of the Company, and as the chairman of the Internal Control Committee and a member of the Audit Committee of the Company, with effect from May 28, 2023.

The biographical details of Mr. Liu are set out as below:

Mr. Liu Chengjiang, aged 60, holds a bachelor’s degree in law from Northwest University of Political Science and Law and a master’s degree in management from New York Institute of Technology, the United States. He is currently a senior partner lawyer of Long An Law Firm. Mr. Liu obtained qualifications to practise as a securities lawyer of the Ministry of Justice and the China Securities Regulatory Commission; defined legal business qualifications for property rights of science and technology enterprises of the State Scientific and Technological Commission and the State-owned Assets Supervision and Administration Commission of the State Council; and the qualification of Chinese tax agent. Mr. Liu is one of the first senior lawyers that are qualified to practise as securities lawyers in the PRC, focusing on securities finance and corporate legal business.

Mr. Liu will enter into a director’s service agreement with the Company for a term of three years commencing from May 28, 2023, which may be terminated by both parties in accordance with the terms of the agreement. Mr. Liu shall hold office until the next following annual general meeting and will be subject to retirement by rotation and re-election at annual general meeting of the Company in accordance with the articles of association of the Company. Pursuant to the service agreement, Mr. Liu will be entitled to a Director’s emolument of HKD330,000 per annum which was determined by the Board with reference to Mr. Liu’s experience, knowledge, qualification, duties and responsibilities and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Mr. Liu (i) has not held any other positions with any members of the Group; (ii) is not related to any director, senior management, substantial shareholder or controlling shareholder of the Company or other members of the Group; (iii) is not interested in the shares of the Company as defined in Part XV of the Securities and Futures Ordinance; and (iv) has not held any other directorships in any other listed public companies in the last three years.

Save as disclosed above, Mr. Liu has confirmed that there is no other information required to be brought to the attention of the shareholders of the Company and the Company or to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited in relation to his appointment as an independent non-executive director of the Company.

Upon the appointment of Mr. Liu, the Company has complied with the requirements set out in Rules 3.10(1), 3.10A and 3.21 of the Listing Rules.

The Board would like to take this opportunity to express its warmest welcome to Mr. Liu in joining the Board.

By Order of the Board
Glory Health Industry Limited
Zhang Zhangsun
Chairman

Beijing, the PRC, May 28, 2023

As at the date of this announcement, the board of directors of the Company comprises Mr. Zhang Zhangsun, Ms. Ruan Wenjuan, Ms. Dong Xueer, Mr. Hao Zhenhe and Mr. Sun Xiaodong as executive directors and Mr. Luo Zhenbang, Mr. Lai Siming and Mr. Liu Chengjiang as independent non-executive directors.